Cn6 - Cost-Effectiveness Model of Midostaurin (Mido) Versus Standard of Care (Soc) in Patients With Newly Diagnosed Flt3 Mutation-Positive (Flt3+) Acute Myeloid Leukemia (Aml): A French Perspective
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.023
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV